Table 3.
Discriminative power of univariate/multivariate selected candidates. Sensitivity and specificity calculated for tumor marker CA125, individual discriminative anti-glycan antibodies and anti-glycan antibody panels (svmLDA03; Galα1-4Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-4-(6-Su)GlcNAcβ, Neu5Acβ2-6GalNAcα, svmLDA06; Galα1-4Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-4-(6-Su)GlcNAcβ, Neu5Acβ2-6GalNAcα, Neu5Acβ2-6Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-3-(6-Su)GalNAcα, Galβ 1-4GlcNAcβ1-6Galβ1-4GlcNAcβ, svmLDA10: Galα1-4Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-4-(6-Su)GlcNAcβ, Neu5Acβ2-6GalNAcα, Neu5Acβ2-6Galβ1-4GlcNAcβ, Neu5Acα2-3Galβ1-3-(6-Su)GalNAcα, Galβ1-4GlcNAcβ1-6Galβ1-4GlcNAcβ, Galβ1-4(6-O-Su)GlcNAcβ, Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ, Galα1-3(Galα1-4)Galβ1-4GlcNAcβ, GlcNAcβ1-3Galβ1-4GlcNAcβ); LN = Galβ1-4GlcNAc.
| Precision- recall break even point | ||
|---|---|---|
| Sensitivity (%) | Specificity (%) | |
|
|
||
| CA125 | 76.0 | 73.9 |
| P1 | 70.8 | 78.8 |
|
|
||
| Chitobiose-Asn | 66.7 | 75.0 |
|
|
||
| GNb6'LN | 66.7 | 75.7 |
|
|
||
| GlcNAcβ1-6'LN | 66.7 | 54.2 |
|
|
||
| Pk | 62.5 | 72.7 |
|
|
||
| svmLDA03 | 75.0 | 81.8 |
|
|
||
| svmLDA06 | 79.2 | 84.8 |
|
|
||
| svmLDA10 | 79.2 | 84.8 |
|
|
||
| LDA/P1-CA125 | 76.0 | 73.9 |
|
|
||